AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a US and China primarily based clinical-stage biotechnology firm devoted to advancing focused oligonucleotide therapies to attain a practical treatment for continual hepatitis B (CHB), closed a USD 73 million Sequence B financing.
The spherical was led by HanKang Capital, with participation from Sherpa Capital, CDH Investments, and a strategic investor, in addition to continued participation from present buyers Qiming Enterprise Companions, InnoPinnacle Fund, and YuanBio Enterprise Capital.
The proceeds will fund the continued Part 2 growth of AHB-137, AusperBio’s lead investigational remedy, supporting each medical research in China and international trials, in addition to the event of commercial-scale manufacturing processes. The funding can even facilitate the enlargement of the corporate’s therapeutic pipeline and operational capabilities to drive sustained development.
Led by Dr. Guofeng Cheng, co-founder and CEO, and Dr. Chris Yang, co-founder and CSO, AusperBio is a clinical-stage biopharmaceutical firm with operations within the USA and China, devoted to advancing oligonucleotide and focused supply applied sciences for therapies, with an preliminary concentrate on curing continual hepatitis B an infection. The corporate has developed a proprietary Med-Oligo™ ASO platform which has been proven to considerably improve the present ASO therapeutics, by means of novel insights into ASO design. Combining with environment friendly focused supply conjugation applied sciences, the modular Med-Oligo™ Platform empowers ASO therapeutics to deal with a broad vary of ailments, together with viral infections, metabolic situations, genetic problems, and immune ailments.
AHB-137, a novel unconjugated antisense oligonucleotide (ASO) developed inside AusperBio’s proprietary Med-Oligo™ ASO expertise platform, was designed to deal with continual hepatitis B for a practical treatment. Its preclinical and Part 1 medical information had been highlighted on the 2023 EASL convention and the 2024 EASL convention, respectively. This novel dual-mechanism ASO has accomplished its international Part 1b trial and is now present process a number of Part 2 trials in China. With its international growth technique, AHB-137 is advancing quickly towards the aim of an HBV treatment.
FinSMEs
27/12/2024
